Literature DB >> 26424563

Androgen deprivation therapy for prostate cancer: friend or foe to the cardiovascular system?

Kaiping Zhang1, Li Zhang1, Zongyao Hao1, Chaozhao Liang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26424563     DOI： 10.1007/s00345-015-1700-7

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  10 in total

1.  Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.

Authors:  Christina G Jespersen; Mette Nørgaard; Michael Borre
Journal:  Eur Urol       Date:  2013-02-12       Impact factor: 20.096

2.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Stephen J Freedland; Matthew R Smith
Journal:  J Natl Cancer Inst       Date:  2012-10-03       Impact factor: 13.506

3.  The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Authors:  Giorgio Gandaglia; Maxine Sun; Ioana Popa; Jonas Schiffmann; Firas Abdollah; Quoc-Dien Trinh; Fred Saad; Markus Graefen; Alberto Briganti; Francesco Montorsi; Pierre I Karakiewicz
Journal:  BJU Int       Date:  2014-07-27       Impact factor: 5.588

4.  Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.

Authors:  Stanislav Ziaran; Frederico Manuel Goncalves; Jan Breza
Journal:  World J Urol       Date:  2012-08-17       Impact factor: 4.226

5.  Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden.

Authors:  Mieke Van Hemelrijck; Hans Garmo; Lars Holmberg; Erik Ingelsson; Ola Bratt; Anna Bill-Axelson; Mats Lambe; Pär Stattin; Jan Adolfsson
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 44.544

6.  Cancer statistics, 2015.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-01-05       Impact factor: 508.702

7.  Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

Authors:  Shabbir M H Alibhai; Minh Duong-Hua; Rinku Sutradhar; Neil E Fleshner; Padraig Warde; Angela M Cheung; Lawrence F Paszat
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

Review 8.  Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

Authors:  Axel S Merseburger; Peter Hammerer; Francois Rozet; Thierry Roumeguère; Orazio Caffo; Fernando Calais da Silva; Antonio Alcaraz
Journal:  World J Urol       Date:  2014-09-27       Impact factor: 4.226

Review 9.  Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research.

Authors:  Rahul A Parikh; Laura E Pascal; Benjamin J Davies; Zhou Wang
Journal:  Asian J Androl       Date:  2014 Jul-Aug       Impact factor: 3.285

Review 10.  Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods.

Authors:  Mark A Moyad
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285
  10 in total
  1 in total

1.  Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.

Authors:  Jesús A Junco; Ranfis Rodríguez; Franklin Fuentes; Idania Baladrón; Maria D Castro; Lesvia Calzada; Carmen Valenzuela; Eddy Bover; Eulogio Pimentel; Roberto Basulto; Niurka Arteaga; Angel Cid-Arregui; Francisco Sariol; Lourdes González; Liliana Porres-Fong; María Medina; Ayni Rodríguez; A Hilda Garay; Osvaldo Reyes; Matilde López; Lourdes de Quesada; Allelin Alvarez; Carolina Martínez; Marleny Marrero; Guillermo Molero; Alfredo Guerra; Pedro Rosales; Carlos Capote; Sahily Acosta; Idania Vela; Lina Arzuaga; Ana Campal; Erlán Ruiz; Elier Rubio; Pável Cedeño; María Carmen Sánchez; Pedro Cardoso; Rolando Morán; Yairis Fernández; Magalys Campos; Henio Touduri; Dania Bacardi; Indalecio Feria; Amilcar Ramirez; Karelia Cosme; Pedro López Saura; Maricel Quintana; Verena Muzio; Ricardo Bringas; Marta Ayala; Mario Mendoza; Luis E Fernández; Adriana Carr; Luis Herrera; Gerardo Guillén
Journal:  Front Oncol       Date:  2019-02-25       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.